AP2461A - Antiviral compounds - Google Patents
Antiviral compoundsInfo
- Publication number
- AP2461A AP2461A AP2007003895A AP2007003895A AP2461A AP 2461 A AP2461 A AP 2461A AP 2007003895 A AP2007003895 A AP 2007003895A AP 2007003895 A AP2007003895 A AP 2007003895A AP 2461 A AP2461 A AP 2461A
- Authority
- AP
- ARIPO
- Prior art keywords
- antiviral compounds
- antiviral
- compounds
- Prior art date
Links
- 230000000840 anti-viral effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/141—Esters of phosphorous acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58863304P | 2004-07-16 | 2004-07-16 | |
| US59163504P | 2004-07-27 | 2004-07-27 | |
| PCT/US2005/025503 WO2006020276A2 (en) | 2004-07-16 | 2005-07-18 | Antiviral compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AP2007003895A0 AP2007003895A0 (en) | 2007-02-28 |
| AP2461A true AP2461A (en) | 2012-09-14 |
Family
ID=35447172
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AP2007003895A AP2461A (en) | 2004-07-16 | 2005-07-18 | Antiviral compounds |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US7642339B2 (es) |
| EP (2) | EP2316839B1 (es) |
| JP (2) | JP5676839B2 (es) |
| KR (1) | KR20070034119A (es) |
| AP (1) | AP2461A (es) |
| AR (1) | AR050174A1 (es) |
| AT (1) | ATE516293T1 (es) |
| AU (1) | AU2005274700B2 (es) |
| BR (1) | BRPI0513426A (es) |
| CA (1) | CA2571984C (es) |
| CY (1) | CY1112453T1 (es) |
| DK (1) | DK1778702T3 (es) |
| EA (1) | EA200700336A1 (es) |
| ES (1) | ES2468441T3 (es) |
| HK (1) | HK1103089A1 (es) |
| HR (2) | HRP20070043A2 (es) |
| IL (1) | IL180288A0 (es) |
| MX (1) | MX2007000584A (es) |
| NO (1) | NO20070866L (es) |
| NZ (1) | NZ552405A (es) |
| PL (2) | PL1778702T3 (es) |
| PT (1) | PT1778702E (es) |
| RS (1) | RS51974B (es) |
| TW (2) | TW200614996A (es) |
| WO (1) | WO2006020276A2 (es) |
Families Citing this family (106)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| US7176208B2 (en) * | 2003-04-18 | 2007-02-13 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors |
| US7273851B2 (en) * | 2003-06-05 | 2007-09-25 | Enanta Pharmaceuticals, Inc. | Tri-peptide hepatitis C serine protease inhibitors |
| US7491794B2 (en) * | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
| US7323447B2 (en) | 2005-02-08 | 2008-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7592336B2 (en) | 2005-05-10 | 2009-09-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7601686B2 (en) | 2005-07-11 | 2009-10-13 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| TWI389908B (zh) * | 2005-07-14 | 2013-03-21 | Gilead Sciences Inc | 抗病毒化合物類 |
| US20090148407A1 (en) * | 2005-07-25 | 2009-06-11 | Intermune, Inc. | Novel Macrocyclic Inhibitors of Hepatitis C Virus Replication |
| ATE493409T1 (de) | 2005-10-11 | 2011-01-15 | Intermune Inc | Verbindungen und verfahren zur inhibierung der replikation des hepatitis-c-virus |
| US7772183B2 (en) | 2005-10-12 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7741281B2 (en) | 2005-11-03 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| PT1966130E (pt) | 2005-12-23 | 2014-01-30 | Zealand Pharma As | Compostos miméticos de lisina modificados |
| RU2008152171A (ru) * | 2006-07-05 | 2010-08-10 | Интермьюн, Инк. (Us) | Новые ингибиторы вирусной репликации гепатита с |
| AP2008004721A0 (en) * | 2006-07-07 | 2008-12-31 | Gilead Sciences Inc | Antiviral phosphinate compounds |
| AU2013200563C1 (en) * | 2006-07-07 | 2015-05-14 | Gilead Sciences, Inc. | Antiviral phosphinate compounds |
| KR20090026216A (ko) * | 2006-07-07 | 2009-03-11 | 길리애드 사이언시즈, 인코포레이티드 | 항바이러스 포스피네이트 화합물 |
| EP2049474B1 (en) | 2006-07-11 | 2015-11-04 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| BRPI0714343A2 (pt) | 2006-07-13 | 2013-03-19 | Achillion Pharmaceuticals Inc | peptÍdeos de 4-amino-4-oxobutanoil como inibidores de replicaÇço viral |
| CA2656816A1 (en) * | 2006-08-04 | 2008-02-14 | Enanta Pharmaceuticals, Inc. | Tetrazolyl macrocyclic hepatitis c serine protease inhibitors |
| US20090035271A1 (en) * | 2007-08-01 | 2009-02-05 | Ying Sun | Tetrazolyl macrocyclic hepatitis c serine protease inhibitors |
| US7582605B2 (en) * | 2006-08-11 | 2009-09-01 | Enanta Pharmaceuticals, Inc. | Phosphorus-containing hepatitis C serine protease inhibitors |
| US7687459B2 (en) * | 2006-08-11 | 2010-03-30 | Enanta Pharmaceuticals, Inc. | Arylalkoxyl hepatitis C virus protease inhibitors |
| CA2663159A1 (en) * | 2006-09-13 | 2008-03-20 | Novartis Ag | Organic compounds and their uses |
| CA2667165A1 (en) * | 2006-10-24 | 2008-05-02 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
| US8343477B2 (en) | 2006-11-01 | 2013-01-01 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
| US7772180B2 (en) | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7763584B2 (en) | 2006-11-16 | 2010-07-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7888464B2 (en) | 2006-11-16 | 2011-02-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8003604B2 (en) | 2006-11-16 | 2011-08-23 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2008070358A2 (en) * | 2006-11-16 | 2008-06-12 | Phenomix Corporation | N-cyclopropyl-hydroxyproline-based tripeptidic hepatitis c serine protease inhibitors containing an isoindole, pyrrolopyridine, pyrrolopyrimidine or pyrrolopyrazine heterocycle in the side chain |
| DK2468724T3 (en) | 2006-12-21 | 2016-02-22 | Zealand Pharma As | Synthesis of pyrrolidine compounds |
| WO2008086053A1 (en) * | 2007-01-03 | 2008-07-17 | Virobay, Inc. | Hcv inhibitors |
| MX2009008541A (es) * | 2007-02-08 | 2009-08-18 | Tibotec Pharm Ltd | Fenilcarbamatos macrociclicos que inhiben el virus de hepatitis c. |
| WO2008096002A1 (en) * | 2007-02-08 | 2008-08-14 | Tibotec Pharmaceuticals Ltd. | Hcv inhibiting macrocyclic phosphonates and amidophosphates |
| US20080287449A1 (en) * | 2007-04-26 | 2008-11-20 | Deqiang Niu | Aza-tripeptide hepatitis c serine protease inhibitors |
| US20080267917A1 (en) * | 2007-04-26 | 2008-10-30 | Deqiang Niu | N-functionalized amides as hepatitis c serine protease inhibitors |
| EP2185524A1 (en) | 2007-05-10 | 2010-05-19 | Intermune, Inc. | Novel peptide inhibitors of hepatitis c virus replication |
| AU2014200403B2 (en) * | 2007-06-29 | 2016-05-19 | Gilead Sciences, Inc. | Antiviral compounds |
| WO2009005677A2 (en) | 2007-06-29 | 2009-01-08 | Gilead Sciences, Inc. | Antiviral compounds |
| AR067180A1 (es) * | 2007-06-29 | 2009-09-30 | Gilead Sciences Inc | Compuestos antivirales |
| KR101596524B1 (ko) * | 2007-06-29 | 2016-02-22 | 길리애드 사이언시즈, 인코포레이티드 | 항바이러스 화합물 |
| US8419332B2 (en) * | 2007-10-19 | 2013-04-16 | Atlas Bolt & Screw Company Llc | Non-dimpling fastener |
| US8383583B2 (en) | 2007-10-26 | 2013-02-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors |
| JP2011503201A (ja) | 2007-11-14 | 2011-01-27 | エナンタ ファーマシューティカルズ インコーポレイテッド | 大環状テトラゾリルｃ型肝炎セリンプロテアーゼ阻害剤 |
| US8263549B2 (en) * | 2007-11-29 | 2012-09-11 | Enanta Pharmaceuticals, Inc. | C5-substituted, proline-derived, macrocyclic hepatitis C serine protease inhibitors |
| US8030307B2 (en) * | 2007-11-29 | 2011-10-04 | Enanta Pharmaceuticals, Inc. | Bicyclic, C5-substituted proline derivatives as inhibitors of the hepatitis C virus NS3 protease |
| WO2009079353A1 (en) | 2007-12-14 | 2009-06-25 | Enanta Pharmaceuticals, Inc. | Triazole-containing macrocyclic hcv serine protease inhibitors |
| US8309685B2 (en) * | 2007-12-21 | 2012-11-13 | Celgene Avilomics Research, Inc. | HCV protease inhibitors and uses thereof |
| NZ586231A (en) | 2007-12-21 | 2012-12-21 | Avila Therapeutics Inc | HCV protease inhibitors comprising a functionalised proline derivative |
| US8202996B2 (en) | 2007-12-21 | 2012-06-19 | Bristol-Myers Squibb Company | Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide |
| US8293705B2 (en) | 2007-12-21 | 2012-10-23 | Avila Therapeutics, Inc. | HCV protease inhibitors and uses thereof |
| AU2008340261C1 (en) * | 2007-12-21 | 2015-12-10 | Celgene Avilomics Research, Inc. | HCV protease inhibitors and uses thereof |
| AU2009210789B2 (en) | 2008-02-04 | 2014-01-30 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
| US8372802B2 (en) | 2008-03-20 | 2013-02-12 | Enanta Pharmaceuticals, Inc. | Fluorinated macrocyclic compounds as hepatitis C virus inhibitors |
| AP2010005416A0 (en) * | 2008-04-15 | 2010-10-31 | Intermune Inc | Novel macrocyclic inhibitors of hepatitis c virus replication. |
| US8163921B2 (en) | 2008-04-16 | 2012-04-24 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8044023B2 (en) | 2008-05-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7964560B2 (en) | 2008-05-29 | 2011-06-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8207341B2 (en) | 2008-09-04 | 2012-06-26 | Bristol-Myers Squibb Company | Process or synthesizing substituted isoquinolines |
| UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
| US8044087B2 (en) | 2008-09-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8563505B2 (en) | 2008-09-29 | 2013-10-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| JP5723783B2 (ja) | 2008-12-10 | 2015-05-27 | アキリオン ファーマシューティカルズ，インコーポレーテッド | ウイルス複製の阻害剤としての新しい４−アミノ−４−オキソブタノイルペプチド |
| US8283310B2 (en) | 2008-12-15 | 2012-10-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| AR075584A1 (es) * | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
| TW201040181A (en) | 2009-04-08 | 2010-11-16 | Idenix Pharmaceuticals Inc | Macrocyclic serine protease inhibitors |
| NZ706236A (en) | 2009-05-13 | 2016-07-29 | Gilead Pharmasset Llc | Antiviral compounds |
| KR20100127948A (ko) * | 2009-05-27 | 2010-12-07 | 한국전자통신연구원 | Ｓａｒｓ 코로나바이러스의 검출 및 억제용 펩타이드 화합물 및 그의 응용 |
| US7924650B2 (en) * | 2009-06-30 | 2011-04-12 | Oracle America, Inc. | Dynamically controlled voltage regulator for a memory |
| US8232246B2 (en) | 2009-06-30 | 2012-07-31 | Abbott Laboratories | Anti-viral compounds |
| TW201117812A (en) | 2009-08-05 | 2011-06-01 | Idenix Pharmaceuticals Inc | Macrocyclic serine protease inhibitors |
| US8927484B2 (en) * | 2009-12-03 | 2015-01-06 | Gilead Sciences, Inc. | Antiviral compounds |
| US8476225B2 (en) | 2009-12-04 | 2013-07-02 | Gilead Sciences, Inc. | Antiviral compounds |
| SG10201509456SA (en) | 2010-11-17 | 2015-12-30 | Gilead Pharmasset Llc | Antiviral compounds |
| CA2822556A1 (en) | 2010-12-30 | 2012-07-05 | Enanta Pharmaceuticals, Inc | Macrocyclic hepatitis c serine protease inhibitors |
| CN103380132B (zh) | 2010-12-30 | 2016-08-31 | 益安药业 | 菲啶大环丙型肝炎丝氨酸蛋白酶抑制剂 |
| WO2012109398A1 (en) | 2011-02-10 | 2012-08-16 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating hcv infections |
| US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| AU2012255029B2 (en) * | 2011-05-19 | 2016-04-28 | Gilead Sciences, Inc. | Processes and intermediates for preparing anti-HIV agents |
| US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| PL3431477T3 (pl) | 2011-11-16 | 2021-04-06 | Gilead Pharmasset Llc | Skondensowane imidazoliloimidazole jako związki przeciwwirusowe |
| US9079887B2 (en) | 2012-05-16 | 2015-07-14 | Gilead Sciences, Inc. | Antiviral compounds |
| US20130309196A1 (en) | 2012-05-16 | 2013-11-21 | Gilead Sciences, Inc. | Antiviral compounds |
| UA119315C2 (uk) | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
| JP2015533124A (ja) | 2012-10-08 | 2015-11-19 | アッヴィ・インコーポレイテッド | Ｈｃｖプロテアーゼ阻害剤を作製するのに有用な化合物 |
| EA025560B1 (ru) | 2012-10-19 | 2017-01-30 | Бристол-Майерс Сквибб Компани | Ингибиторы вируса гепатита с |
| WO2014070964A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| WO2014071007A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2914614B1 (en) | 2012-11-05 | 2017-08-16 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US9233974B2 (en) | 2012-12-21 | 2016-01-12 | Gilead Sciences, Inc. | Antiviral compounds |
| WO2014137869A1 (en) | 2013-03-07 | 2014-09-12 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| AU2014227849A1 (en) | 2013-03-15 | 2015-10-01 | Achillion Pharmaceuticals, Inc. | Sovaprevir polymorphs and methods of manufacture thereof |
| US9085607B2 (en) | 2013-03-15 | 2015-07-21 | Achillion Pharmaceuticals, Inc. | ACH-0142684 sodium salt polymorph, composition including the same, and method of manufacture thereof |
| SG11201507223TA (en) | 2013-03-15 | 2015-10-29 | Gilead Sciences Inc | Macrocyclic and bicyclic inhibitors of hepatitis c virus |
| US9006423B2 (en) | 2013-03-15 | 2015-04-14 | Achillion Pharmaceuticals Inc. | Process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof |
| US9962251B2 (en) | 2013-10-17 | 2018-05-08 | Boston Scientific Scimed, Inc. | Devices and methods for delivering implants |
| WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
| RS62434B1 (sr) | 2014-12-26 | 2021-11-30 | Univ Emory | Antivirusni n4-hidroksicitidin derivati |
| MX2018014377A (es) | 2016-05-27 | 2019-03-14 | Gilead Sciences Inc | Metodos para tratar infecciones por virus de hepatitis b usando inhibidores de proteina no estructural 5a (ns5a), proteina no estructural 5b (ns5b) o proteina no estructural 3 (ns3). |
| DK3618847T3 (da) | 2017-05-05 | 2021-05-25 | Boston Medical Ct Corp | GAP-junction-modulatorer af intercellulær kommunikation og deres anvendelse til behandling af diabetisk øjensygdom |
| PL3661937T3 (pl) | 2017-08-01 | 2021-12-20 | Gilead Sciences, Inc. | Formy krystaliczne ((s)-((((2r,5r)-5-(6-amino-9h-puryn-9-ylo)-4-fluoro-2,5-dihydrofuran-2-ylo)oksy)metylo)(fenoksy)fosforylo)-l-alaninianu etylu (gs-9131) do leczenia zakażeń wirusowych |
| CN111372592A (zh) | 2017-12-07 | 2020-07-03 | 埃默里大学 | N4-羟基胞苷及衍生物和与其相关的抗病毒用途 |
| CN110892989B (zh) * | 2019-06-27 | 2023-03-14 | 内蒙古伊利实业集团股份有限公司 | 一种具有缓解便秘功能的副干酪乳杆菌et-22 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002060926A2 (en) * | 2000-11-20 | 2002-08-08 | Bristol-Myers Squibb Company | Hepatitis c tripeptide inhibitors |
| WO2003064455A2 (en) * | 2002-01-30 | 2003-08-07 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis c virus |
| WO2003064416A1 (en) * | 2002-02-01 | 2003-08-07 | Boehringer Ingelheim International Gmbh | Heterocyclic tripeptides as hepatitis c inhibitors |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816570A (en) | 1982-11-30 | 1989-03-28 | The Board Of Regents Of The University Of Texas System | Biologically reversible phosphate and phosphonate protective groups |
| US4968788A (en) | 1986-04-04 | 1990-11-06 | Board Of Regents, The University Of Texas System | Biologically reversible phosphate and phosphonate protective gruops |
| DK0533833T3 (da) | 1990-06-13 | 1996-04-22 | Arnold Glazier | Phosphorprolægemidler |
| EP0481214B1 (en) | 1990-09-14 | 1998-06-24 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Prodrugs of phosphonates |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| EP2409985A3 (en) * | 1996-10-18 | 2013-05-01 | Vertex Pharmaceuticals Incorporated | Inhibitors de serine proteases, especially of the NS3 protease of the hepatitis C virus |
| AU7890398A (en) * | 1996-12-26 | 1998-07-31 | Shionogi & Co., Ltd. | Process for the preparation of carbamoyllated imidazole derivatives |
| ES2241157T3 (es) * | 1997-08-11 | 2005-10-16 | Boehringer Ingelheim (Canada) Ltd. | Peptidos inhibidores de la hepatitis c. |
| US6312662B1 (en) * | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
| US6323180B1 (en) * | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| US6608027B1 (en) * | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
| UA74546C2 (en) * | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
| BR0206806A (pt) * | 2001-01-31 | 2004-02-03 | Warner Lambert Co | Método para carbamoilação de álcoois |
| US6867185B2 (en) * | 2001-12-20 | 2005-03-15 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
| US7119072B2 (en) * | 2002-01-30 | 2006-10-10 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis C virus |
| US7091184B2 (en) * | 2002-02-01 | 2006-08-15 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
| CA2370396A1 (en) * | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
| US6828301B2 (en) * | 2002-02-07 | 2004-12-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
| WO2003099316A1 (en) * | 2002-05-20 | 2003-12-04 | Bristol-Myers Squibb Company | Heterocyclicsulfonamide hepatitis c virus inhibitors |
| AU2003299519A1 (en) * | 2002-05-20 | 2004-05-04 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| MY140680A (en) * | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
-
2005
- 2005-07-18 NZ NZ552405A patent/NZ552405A/en not_active IP Right Cessation
- 2005-07-18 BR BRPI0513426-9A patent/BRPI0513426A/pt not_active IP Right Cessation
- 2005-07-18 ES ES10178084.9T patent/ES2468441T3/es active Active
- 2005-07-18 AT AT05791144T patent/ATE516293T1/de active
- 2005-07-18 US US11/184,429 patent/US7642339B2/en active Active
- 2005-07-18 WO PCT/US2005/025503 patent/WO2006020276A2/en active Application Filing
- 2005-07-18 PL PL05791144T patent/PL1778702T3/pl unknown
- 2005-07-18 CA CA2571984A patent/CA2571984C/en not_active Expired - Fee Related
- 2005-07-18 EP EP10178084.9A patent/EP2316839B1/en active Active
- 2005-07-18 PL PL382845A patent/PL382845A1/pl not_active Application Discontinuation
- 2005-07-18 PT PT05791144T patent/PT1778702E/pt unknown
- 2005-07-18 EP EP05791144A patent/EP1778702B1/en active Active
- 2005-07-18 RS RS20110436A patent/RS51974B/en unknown
- 2005-07-18 JP JP2007521717A patent/JP5676839B2/ja not_active Expired - Fee Related
- 2005-07-18 KR KR1020077003918A patent/KR20070034119A/ko active IP Right Grant
- 2005-07-18 AR ARP050102967A patent/AR050174A1/es not_active Application Discontinuation
- 2005-07-18 US US11/632,180 patent/US20080311077A1/en not_active Abandoned
- 2005-07-18 AP AP2007003895A patent/AP2461A/xx active
- 2005-07-18 DK DK05791144.8T patent/DK1778702T3/da active
- 2005-07-18 AU AU2005274700A patent/AU2005274700B2/en not_active Ceased
- 2005-07-18 EA EA200700336A patent/EA200700336A1/ru unknown
- 2005-07-18 MX MX2007000584A patent/MX2007000584A/es active IP Right Grant
- 2005-07-19 TW TW094124376A patent/TW200614996A/zh unknown
- 2005-07-19 TW TW101104372A patent/TW201228665A/zh unknown
-
2006
- 2006-12-25 IL IL180288A patent/IL180288A0/en unknown
-
2007
- 2007-02-09 HR HR20070043A patent/HRP20070043A2/xx not_active Application Discontinuation
- 2007-02-15 NO NO20070866A patent/NO20070866L/no not_active Application Discontinuation
- 2007-10-26 HK HK07111565.5A patent/HK1103089A1/xx unknown
-
2011
- 2011-10-10 CY CY20111100970T patent/CY1112453T1/el unknown
- 2011-10-11 HR HR20110732T patent/HRP20110732T1/hr unknown
-
2012
- 2012-02-06 JP JP2012023052A patent/JP5767984B2/ja not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002060926A2 (en) * | 2000-11-20 | 2002-08-08 | Bristol-Myers Squibb Company | Hepatitis c tripeptide inhibitors |
| WO2003064455A2 (en) * | 2002-01-30 | 2003-08-07 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis c virus |
| WO2003064416A1 (en) * | 2002-02-01 | 2003-08-07 | Boehringer Ingelheim International Gmbh | Heterocyclic tripeptides as hepatitis c inhibitors |
Non-Patent Citations (1)
| Title |
|---|
| ORVIETO F ET AL: "Novel, potent phenethylamide inhibitors of the hepatitis C virus (HCV) NS3 protease: Probing the role of P2 aryloxyprolines with hybrid structures" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 13, no. 16, 18 August 2003 (2003-08-18), pages 2745-2748, XP002314396 ISSN: 0960-894X * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP2461A (en) | Antiviral compounds | |
| IL180758A0 (en) | Antiviral compounds | |
| IL181219A0 (en) | Heterocyclic antiviral compounds | |
| IL179534A0 (en) | Heterocyclic antiviral compounds | |
| EP1737831A4 (en) | NEUROLOGICALLY ACTIVE COMPOUNDS | |
| EP1893629A4 (en) | ANTIVIRAL CONNECTIONS | |
| GB0412914D0 (en) | Compounds | |
| EP1755617A4 (en) | PERFLUORCARBON-SOLUBLE COMPOUNDS | |
| GB0405193D0 (en) | Compounds | |
| GB0405267D0 (en) | Compounds | |
| GB0405101D0 (en) | Compounds | |
| GB0401269D0 (en) | Compounds | |
| ZA200701118B (en) | Antiviral compounds | |
| GB0403593D0 (en) | Compounds | |
| GB0403595D0 (en) | Compounds | |
| GB0414327D0 (en) | Antiviral composition | |
| GB0405636D0 (en) | Antiviral composition | |
| GB0413518D0 (en) | Antiviral composition | |
| EP1707210A4 (en) | ANTIVIRAL PREPARATIONS | |
| GB0401656D0 (en) | Compounds | |
| GB0405198D0 (en) | Compounds | |
| GB0403334D0 (en) | Compounds | |
| GB0401657D0 (en) | Compounds | |
| GB0401654D0 (en) | Compounds | |
| GB0403594D0 (en) | Compounds |